RecruitingInterventionalPhase 2

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2

NCT ID: NCT04879329Sponsor: Seagen, a wholly owned subsidiary of PfizerLast updated: 2026-04-21

Summary

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.

Arms & interventions

Drugdisitamab vedotin
Given into the vein (IV; intravenous) every 2 weeks.
Drugpembrolizumab
Given by IV on Day 1 of each 6-week cycle.

Outcome measures

Primary

Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A, B, C, and G)
The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1
Time frame: Duration of treatment; approximately 2 years
Incidence of adverse events (AEs) (Cohorts D and E)
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Time frame: Approximately 2 years
Incidence of dose alterations (Cohorts D and E)
Time frame: Approximately 2 years
Incidence of laboratory abnormalities (Cohorts D and E)
To be summarized using descriptive statistics.
Time frame: Approximately 2 years
Incidence of electrocardiogram (ECG) abnormalities (Cohorts D and E)
Time frame: Approximately 2 years
Change from baseline of left ventricular ejection fraction (LVEF) (Cohorts D and E)
Time frame: Approximately 2 years
Pharmacokinetic (PK) parameter - Area under the curve (AUC) (Cohorts D and E)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Maximum concentration (Cmax) (Cohorts D and E)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Time to maximum concentration (Tmax) (Cohorts D and E)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Trough concentration (Ctrough) (Cohorts D and E)
To be summarized using descriptive statistics.
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

Secondary

cORR per RECIST v1.1 by investigator assessment (Cohorts A, B, C, and G)
Time frame: Duration of treatment; approximately 2 years
Confirmed Duration of Response (DOR) per RECIST v1.1 by BICR (Cohorts A, B, C, and G)
Time frame: From start of treatment to completion of response assessment; approximately 2 years
Confirmed DOR per RECIST v1.1 by investigator assessment (Cohorts A, B, C, and G)
Time frame: From start of treatment to completion of response assessment; approximately 2 years
Progression-free survival (PFS) per RECIST v1.1 by BICR (Cohorts A, B, C, and G)
Time frame: From start of treatment to completion of response assessment; approximately 2 years
PFS per RECIST v1.1 by investigator assessment (Cohorts A, B, C, and G)
Time frame: From start of treatment to completion of response assessment; approximately 2 years
Disease control rate (DCR) per RECIST v1.1 by BICR (Cohorts A, B, C, and G)
Time frame: From start of treatment to completion of response assessment; approximately 2 years
DCR per RECIST v1.1 by investigator (Cohorts A, B, C, and G)
Time frame: From start of treatment to completion of response assessment; approximately 2 years
Overall survival (OS) (Cohorts A, B, C, and G)
Time frame: Duration of study; approximately 3 years
Incidence of adverse events (AEs) (Cohorts A, B, C, and G)
Time frame: Approximately 2 years
Incidence of dose alterations (Cohorts A, B, C, and G)
Time frame: Approximately 2 years
Incidence of laboratory abnormalities (Cohorts A, B, C, and G)
Time frame: Approximately 2 years
Incidence of ECG abnormalities (Cohorts A, B, C, and G)
Time frame: Approximately 2 years
Change from baseline of LVEF (Cohorts A, B, C, and G)
Time frame: Approximately 2 years
PK parameter - AUC (Cohorts A, B, C, and G)
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Cmax (Cohorts A, B, C, and G)
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Tmax (Cohorts A, B, C, and G)
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter - Ctrough (Cohorts A, B, C, and G)
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
PK parameter of pembrolizumab - Cmax (Cohort E)
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
Incidence of anti-drug antibodies (ADAs) against disitamab vedotin (All Cohorts)
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
Incidence of anti-drug antibodies (ADAs) against pembrolizumab (Cohorts C and E)
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years
Incidence of neutralizing antibodies (NABs) against disitamab vedotin (All Cohorts)
Time frame: Through 30-37 days following the last dose of DV; up to approximately 2 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No

Inclusion Criteria: Cohorts A and B * Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra * Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of platinum-containing chemotherapy * At least one measurable lesion by investigator assessment based on RECIST version 1.1. * HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Cohort C * Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra * No prior systemic therapy for LA/mUC * Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy * At least one measurable lesion by investigator assessment based on RECIST v1.1. * Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation * HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, on the provided tumor tissue sample * ECOG performance status of 0, 1, or 2 Cohort D * Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra * Based on a participant's eligibility to receive treatment with standard of care therapies in Japan, participants must have received all of the following lines of therapy for LA/mUC: * a. One prior line of platinum-containing chemotherapy. * b. Prior therapy with PD-(L)1 inhibitors as (neo)adjuvant therapy, first-line maintenance therapy or as second line treatment. * c. Prior enfortumab vedotin therapy. * At least one measurable lesion by investigator assessment based on RECIST v1.1. * ECOG performance status of 0 or 1 Cohort E * Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra * No prior systemic therapy for LA/mUC * Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy. * At least one measurable lesion by investigator assessment based on RECIST v1.1. * Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation * HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample * ECOG performance status of 0 or 1 Cohort G * Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra * Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of therapy containing enfortumab vedotin as monotherapy or in combination with pembrolizumab * The last administration of enfortumab vedotin must be 90 days from the start of study treatment. Intervening therapies are allowed between the final dose of enfortumab vedotin and the start of disitamab vedotin. * At least one measurable lesion by investigator assessment based on RECIST version 1.1. * HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Exclusion Criteria: Cohorts A and B * Known hypersensitivity to disitamab vedotin or any of their components * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohorts A and B) * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia) * Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy * Major surgery that has not fully recovered within 4 weeks prior to dose administration * Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline Cohort C * Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study defined as Cycle 1 Day 1 for the single-arm part of Cohort C and as randomization date for the randomized part of Cohort C) * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia) * Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy * Major surgery that has not fully recovered within 4 weeks prior to dose administration * Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug * Participants who have previously received any prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, CTLA-4 inhibitors, or OX-40 agonists) are excluded. Cohort D * Known hypersensitivity to disitamab vedotin or any of their components * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort D) * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia) * Prior HER2-directed therapy * Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy * Major surgery that has not fully recovered within 4 weeks prior to dose administration * Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline Cohort E * Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort E) * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia) * Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy * Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy * Major surgery that has not fully recovered within 4 weeks prior to dose administration * Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug Cohort G * Known hypersensitivity to disitamab vedotin or any of their components * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort G) * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia) * Prior HER2-directed therapy * Major surgery that has not fully recovered within 4 weeks prior to dose administration * Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.

Study locations (159)

Banner Gateway Medical Center

Gilbert, Arizona, 85234

Recruiting

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234

Recruiting

Kaiser Permanente Anaheim Kraemer Medical Offices

Anaheim, California, 92806

Recruiting

Foothill Cardioology

Arcadia, California, 91007

Recruiting

Kaiser Permanente Baldwin Park Medical Center

Baldwin Park, California, 91706

Recruiting

Kaiser Permanente Bellflower Medical Offices

Bellflower, California, 90706

Recruiting

Beverly Hills Multi-Specialties Practice

Beverly Hills, California, 90211

Recruiting

Providence Saint Joseph Medical Center

Burbank, California, 91505

Recruiting

UCLA Burbank Cardiology

Burbank, California, 91505

Recruiting

UCLA Hematology/Oncology - Burbank

Burbank, California, 91505

Recruiting

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Duarte, California, 91010

Active Not Recruiting

UCLA Encino Specialty Care (Radiology)

Encino, California, 91436

Recruiting

UCLA Hematology/Oncoclogy-Encino

Encino, California, 91436

Recruiting

Kaiser Permanente Fontana Medical Center

Fontana, California, 92335

Recruiting

Foothill Cardiology Glendora

Glendora, California, 91741

Recruiting

Kaiser Permanente South Bay Medical center

Harbor City, California, 90710

Recruiting

Chao Family Comprehensive Cancer Center and Ambulatory Care

Irvine, California, 92612

Recruiting

Kaiser Permanente Alton/Sand Canyon Medical Offices

Irvine, California, 92618

Recruiting

UCLA Downtown Los Angeles Primary & Specialty Care

Los Angeles, California, 90017

Recruiting

Kaiser Permanente Los Angeles Medical Offices

Los Angeles, California, 90027

Recruiting

Kaiser Permanente West Los Angeles Medical Center

Los Angeles, California, 90034

Recruiting

Valkyrie Clinical Trials

Los Angeles, California, 90067

Not Yet Recruiting

Ronald Reagan UCLA Medical Center, Drug Information Center

Los Angeles, California, 90095

Recruiting

UCLA Cardiovascular Center

Los Angeles, California, 90095

Recruiting

UCLA Hematology Oncology

Los Angeles, California, 90095

Recruiting

UCLA Westwood Specialty Care

Los Angeles, California, 90095

Recruiting

UCLA Santa Monica Cardiology

Los Angeles, California, 90404

Recruiting

UCLA Montecito Primary & Specialty Care

Montecito, California, 93108

Recruiting

Newport Diagnostics Center (Radiology)

Newport Beach, California, 92660

Recruiting

Kaiser Permanente Ontario Medical Center

Ontario, California, 91761

Recruiting

UC Irvine Health

Orange, California, 92868

Recruiting

Kaiser Permanente Panorama City Medical Center, Medical Offices 3

Panorama City, California, 91402

Recruiting

Foothill Cardiology Pasadena

Pasadena, California, 91105

Recruiting

Southern California Heart Specialists

Pasadena, California, 91105

Recruiting

UCLA Hematology/ Oncology- Pasadena

Pasadena, California, 91105

Recruiting

UCLA Hematology Oncology - Porter Ranch

Porter Ranch, California, 91326

Recruiting

UCLA Porter Ranch Primary & Specialty Care

Porter Ranch, California, 91326

Recruiting

Kaiser Permanente Riverside Medical Center

Riverside, California, 92505

Recruiting

Southern California Permanente Medical Group (SCPMG)

Riverside, California, 92505

Recruiting

Kaiser Permanente San Diego Mission Road (Regulatory and Lab Supplies)

San Diego, California, 92108

Recruiting

Kaiser Permanente Zion Medical Center

San Diego, California, 92120

Recruiting

UCSF Cancer Center MZ Phlebotomy

San Francisco, California, 94115

Recruiting

UCSF Mount Zion Phlebotomy

San Francisco, California, 94115

Recruiting

UCSF Parnassus Phlebotomy

San Francisco, California, 94143

Recruiting

UCSF Investigational Drugs Pharmacy

San Francisco, California, 94158

Recruiting

University of California, San Francisco | HDFCCC - Hematopoietic Malignancies

San Francisco, California, 94158

Recruiting

University of California, San Francisco

San Francisco, California, 94158

Recruiting

Diagnostic Medical Group of Southern California (Radiology)

San Gabriel, California, 91776

Recruiting

Southern California Heart Centers

San Gabriel, California, 91776

Recruiting

UCLA Hematology/Oncology - San Luis Obispo

San Luis Obispo, California, 93401

Recruiting

Sierra Vista Regional Medical Center

San Luis Obispo, California, 93405

Recruiting

Kaiser Permanente San Marcos Medical Offices

San Marcos, California, 92078

Recruiting

UCLA Hematology/Oncology - Santa Monica

Santa Monica, California, 90404

Recruiting

UCLA Simi Valley Alamo Specialty Care

Simi Valley, California, 93065

Recruiting

Twin Cities Community Hospital

Templeton, California, 93465

Recruiting

UCLA Thousand Oaks Primary & Specialty Care

Thousand Oaks, California, 91360

Recruiting

UCLA Hematology/Oncology - Torrance

Torrance, California, 90505

Recruiting

UCLA Torrance Lomita Specialty Care

Torrance, California, 90505

Recruiting

UCLA Hematology-Oncology Clinic - Santa Clarita

Valencia, California, 91355

Recruiting

UCLA Santa Clarita Primary & Specialty Care

Valencia, California, 91355

Recruiting

UCLA Hematology/Oncology - Ventura

Ventura, California, 93003

Recruiting

UCLA Ventura Cardiology

Ventura, California, 93003

Recruiting

UCLA Hematology/Oncology - Westlake

Westlake Village, California, 91361

Recruiting

Kaiser Permanente Woodland Hills Medical Center

Woodland Hills, California, 91367

Recruiting

Medstar Washington Hospital Center

Washington D.C., District of Columbia, 20010

Not Yet Recruiting

Florida Cancer Specialists

Bonita Springs, Florida, 34135

Recruiting

Florida Cancer Specialists

Bradenton, Florida, 34205

Recruiting

Florida Cancer Specialists

Bradenton, Florida, 34211

Recruiting

Florida Cancer Specialists

Cape Coral, Florida, 33909

Recruiting

Florida Cancer Specialists

Daytona Beach, Florida, 32117

Active Not Recruiting

Florida Cancer Specialists

Fleming Island, Florida, 32003

Recruiting

Florida Cancer Specialists

Fort Myers, Florida, 33905

Recruiting

Florida Cancer Specialists

Fort Myers, Florida, 33908

Recruiting

Florida Cancer Specialists

N. Venice, Florida, 34275

Recruiting

Florida Cancer Specialists

Naples, Florida, 34102

Recruiting

Florida Cancer Specialists

Port Charlotte, Florida, 33980

Recruiting

Florida Cancer Specialists

Sarasota, Florida, 34232

Recruiting

Florida Cancer Specialists Sarasota Memorial Hospital (SAD)

Sarasota, Florida, 34239

Recruiting

Florida Cancer Specialists

Stuart, Florida, 34994

Active Not Recruiting

Florida Cancer Specialists

Tallahassee, Florida, 32308

Recruiting

Moffitt Cancer Center McKinley Hospital

Tampa, Florida, 33612

Recruiting

Moffitt Cancer Center

Tampa, Florida, 33612

Recruiting

Florida Cancer Specialists

Venice, Florida, 34285

Recruiting

Florida Cancer Specialists

Venice, Florida, 34292

Recruiting

Florida Cancer Specialists

Vero Beach, Florida, 32960

Active Not Recruiting

Florida Cancer Specialists

Wellington, Florida, 33414

Active Not Recruiting

Florida Cancer Specialists

West Palm Beach, Florida, 33401

Active Not Recruiting

Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica

Carrollton, Georgia, 30117

Active Not Recruiting

West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica

Carrollton, Georgia, 30117

Active Not Recruiting

Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital

Cartersville, Georgia, 30121

Active Not Recruiting

Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital

Douglasville, Georgia, 30134

Active Not Recruiting

Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital

Hiram, Georgia, 30141

Active Not Recruiting

WellStar Paulding Hospital

Hiram, Georgia, 30141

Active Not Recruiting

Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital

Marietta, Georgia, 30060

Active Not Recruiting

UChicago Medicine - River East

Chicago, Illinois, 60611

Recruiting

University of Chicago Medical Center

Chicago, Illinois, 60637

Recruiting

Accellacare - Deerfield

Deerfield, Illinois, 60015

Recruiting

UChicago Medicine at Ingalls - Flossmoor

Flossmoor, Illinois, 60422

Recruiting

UChicago Medicine Ingalls Memorial

Harvey, Illinois, 60426

Recruiting

University of Chicago Comprehensive Cancer Center at Silver Cross Hospital

New Lenox, Illinois, 60451

Recruiting

The University of Chicago Medicine Center for Advanced Care Orland Park

Orland Park, Illinois, 60462

Recruiting

UChicago Medicine at Ingalls - Tinley Park

Tinley Park, Illinois, 60477

Recruiting

UMass Memorial Medical Center

Worcester, Massachusetts, 01655

Recruiting

University of Massachusetts Chan Medical School

Worcester, Massachusetts, 01655

Recruiting

The Cancer & Hematology Centers

Big Rapids, Michigan, 49307

Recruiting

Karmanos Cancer Institute

Detroit, Michigan, 48201

Recruiting

Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)

Detroit, Michigan, 48202

Recruiting

Karmanos Cancer Institute Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334

Recruiting

The Cancer & Hematology Centers

Grand Rapids, Michigan, 49503

Recruiting

Cancer & Hematology Centers of Western Michigan, PC- Kit Storage

Grand Rapids, Michigan, 49546

Recruiting

The Cancer & Hematology Centers

Grand Rapids, Michigan, 49546

Recruiting

The Cancer & Hematology Centers

Holland, Michigan, 49424

Recruiting

Karmanos Cancer Institute at McLaren Greater Lansing

Lansing, Michigan, 48910

Recruiting

The Cancer & Hematology Centers

Norton Shores, Michigan, 49444

Recruiting

MSK Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting

MSK Monmouth

Middletown, New Jersey, 07748

Recruiting

MSK Bergen

Montvale, New Jersey, 07645

Recruiting

MSK Commack

Commack, New York, 11725

Recruiting

MSK Wesrchester

Harrison, New York, 10604

Recruiting

Northwell Health

Lake Success, New York, 11042

Active Not Recruiting

Memorial Sloan Kattering Cancer Centre- Investigational Drug Service Pharmacy

Long Island City, New York, 11101

Recruiting

Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).

New York, New York, 10021

Recruiting

Icahn School of Medicine at Mount Sinai

New York, New York, 10029

Recruiting

Evelyn H. Lauder Breast and Imaging Centre (BAIC)

New York, New York, 10065

Recruiting

Memorial Sloan Kettering Cancer Center - Main Campus

New York, New York, 10065

Recruiting

Sidney Kimmel Center for Prostate and Urological Cancers - Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting

SUNY Upstate Medical University

Syracuse, New York, 13210

Active Not Recruiting

MSK nassau

Uniondale, New York, 11553

Recruiting

UNC Hospitals, The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27514

Not Yet Recruiting

UNC Lineberger Comprehensive Cancer Center / University of North Carolina

Chapel Hill, North Carolina, 27599

Not Yet Recruiting

Carolinas Medical Center (biopsy only)

Charlotte, North Carolina, 28203

Recruiting

Carolinas Medical Center Investigational Drug Services

Charlotte, North Carolina, 28204

Recruiting

Levine Cancer Institute

Charlotte, North Carolina, 28204

Recruiting

Atrium Health Mercy (biopsy only)

Charlotte, North Carolina, 28207

Recruiting

Atrium Health University City (biopsy only)

Charlotte, North Carolina, 28262

Recruiting

Levine Cancer Institute University

Charlotte, North Carolina, 28262

Recruiting

Levine Cancer Institute - Ballantyne

Charlotte, North Carolina, 28277

Recruiting

Atrium Health Cabarrus (biopsy only)

Concord, North Carolina, 28025

Recruiting

Levine Cancer Institute Concord

Concord, North Carolina, 28025

Recruiting

Levine Cancer Institute- Gaston

Gastonia, North Carolina, 28054

Recruiting

Atrium Health Union (biopsy only)

Monroe, North Carolina, 28112

Recruiting

University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106

Recruiting

Ohio State University Hospital

Columbus, Ohio, 43210

Recruiting

Ohio State University

Columbus, Ohio, 43210

Recruiting

OSU Wexner Medical Center & James Cancer Hospital

Columbus, Ohio, 43210

Recruiting

OSU Wexner Medical Center, Investigational Drug Services

Columbus, Ohio, 43210

Recruiting

The James Cancer Hospital & Solove Research Institute at The OSU Comprehensive Cancer Center

Columbus, Ohio, 43210

Recruiting

The James Outpatient Care West Campus

Columbus, Ohio, 43221

Recruiting

OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104

Recruiting

OU Medical Center

Oklahoma City, Oklahoma, 73104

Recruiting

University of Tennessee Medical Center

Knoxville, Tennessee, 37920

Recruiting

Baylor Scott and White Research Institute

Dallas, Texas, 75204

Not Yet Recruiting

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030

Recruiting

Baylor Scott & White Medical Center - Temple

Temple, Texas, 76508

Not Yet Recruiting

Inova Schar Cancer Institute

Fairfax, Virginia, 22031

Recruiting

Harborview Medical Center

Seattle, Washington, 98104

Recruiting

Fred Hutchinson Cancer Center

Seattle, Washington, 98109

Recruiting

University of Washington Medical Center

Seattle, Washington, 98195

Recruiting

Froedtert Hospital/Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Recruiting